MedTrace Logo

Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections

NCT06379542 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2024-04-23

No results posted yet for this study

Summary

The study is planned to evaluate the therapeutic efficacy and safety of XC8, film-coated tablets, in the treatment of dry non-productive cough on the background of acute respiratory infections in children from 6 to 17 years compared with placebo.

Conditions

  • Acute Respiratory Infection

Interventions

DRUG

XC8

40 mg/day or 80 mg/day for 7-14 days

DRUG

Placebo

2 tablets/day for 7-14 days

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-04
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06379542 on ClinicalTrials.gov